116 related articles for article (PubMed ID: 18087819)
1. Effect of probenecid on the biliary excretion of belotecan.
Namkoong EM; Kim IW; Kim DD; Chung SJ; Shim CK
Arch Pharm Res; 2007 Nov; 30(11):1482-8. PubMed ID: 18087819
[TBL] [Abstract][Full Text] [Related]
2. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
Li H; Jin HE; Kim W; Han YH; Kim DD; Chung SJ; Shim CK
Pharm Res; 2008 Nov; 25(11):2601-12. PubMed ID: 18654741
[TBL] [Abstract][Full Text] [Related]
3. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
BMC Med; 2004 May; 2():16. PubMed ID: 15125776
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.
Tian X; Zamek-Gliszczynski MJ; Li J; Bridges AS; Nezasa K; Patel NJ; Raub TJ; Brouwer KL
Drug Metab Dispos; 2008 Jan; 36(1):61-4. PubMed ID: 17913796
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver.
Ahmed S; Vo NT; Thalhammer T; Thalhammer F; Gattringer KB; Jäger W
J Pharm Pharmacol; 2008 Jan; 60(1):55-62. PubMed ID: 18088505
[TBL] [Abstract][Full Text] [Related]
6. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Huisman MT; Chhatta AA; van Tellingen O; Beijnen JH; Schinkel AH
Int J Cancer; 2005 Sep; 116(5):824-9. PubMed ID: 15849751
[TBL] [Abstract][Full Text] [Related]
7. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter.
Smeets PH; van Aubel RA; Wouterse AC; van den Heuvel JJ; Russel FG
J Am Soc Nephrol; 2004 Nov; 15(11):2828-35. PubMed ID: 15504935
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.
Mallants R; Van Oosterwyck K; Van Vaeck L; Mols R; De Clercq E; Augustijns P
Xenobiotica; 2005; 35(10-11):1055-66. PubMed ID: 16393861
[TBL] [Abstract][Full Text] [Related]
9. Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Apr; 59(4):513-20. PubMed ID: 17430634
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
Maier-Salamon A; Hagenauer B; Reznicek G; Szekeres T; Thalhammer T; Jäger W
J Pharm Sci; 2008 Apr; 97(4):1615-28. PubMed ID: 17724663
[TBL] [Abstract][Full Text] [Related]
11. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Yokooji T; Kawabe Y; Mori N; Murakami T
J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
13. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
14. Secretory transport of p-aminohippuric acid across intestinal epithelial cells in Caco-2 cells and isolated intestinal tissue.
Naruhashi K; Tamai I; Sai Y; Suzuki N; Tsuji A
J Pharm Pharmacol; 2001 Jan; 53(1):73-81. PubMed ID: 11206195
[TBL] [Abstract][Full Text] [Related]
15. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Horikawa M; Kato Y; Sugiyama Y
Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
[TBL] [Abstract][Full Text] [Related]
16. Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat.
Savina PM; Brouwer KL
Drug Metab Dispos; 1992; 20(4):496-501. PubMed ID: 1356724
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment.
Xiong H; Suzuki H; Sugiyama Y; Meier PJ; Pollack GM; Brouwer KL
Drug Metab Dispos; 2002 Sep; 30(9):962-9. PubMed ID: 12167560
[TBL] [Abstract][Full Text] [Related]
19. Role of rat multidrug resistance protein 2 in plasma and biliary disposition of dibromosulfophthalein after microsomal enzyme induction.
Johnson DR; Klaassen CD
Toxicol Appl Pharmacol; 2002 Apr; 180(1):56-63. PubMed ID: 11922777
[TBL] [Abstract][Full Text] [Related]
20. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
